Noom’s new Microdose GLP-1 program
from The Refill, by MM+M Hosted by Geoff Cook, Jeffery Egler, Lecia Bushak
In this episode, MM+M Pharma Editor Lecia Bushak sits down with Noom’s CEO Geoff Cook and Chief Medical Officer Dr. Jeffrey Egler to discuss the launch of their new Microdose GLP-1 program, designed to help people lose weight with smaller doses of the popular obesity drugs. They delve into the benefits of “micro-dosing” GLP-1s and the behavioral health components of Noom’s model that aims to support long-term weight loss. Egler and Cook break down the challenges of drug pricing and accessibility, as well as the future of the obesity market. Is your team still treating AI like a side experiment while competitors use it to win? Cut through the buzzword fatigue. On November 12th, join hundreds of top marketers in New York City for AI Deciphered, presented by Campaign, MM+M, and PRWeek. Get real-world playbooks from leaders like Reddit’s Rob Gaige and Yahoo’s Matt Sanchez across dedicated tracks built for daily execution. Check us out at: mmm-online.com Follow us: YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Embed this episode
What this episode covers
Noom CEO Geoff Cook and Chief Medical Officer Dr. Jeffrey Egler break down the company’s new Microdose GLP-1 program.
No transcript yet.